Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aileron Therapeutics, Inc.
Evopoint Biosciences Inc.
Masonic Cancer Center, University of Minnesota
Assistance Publique - Hôpitaux de Paris
National Institutes of Health Clinical Center (CC)
BeiGene
Incyte Corporation
Georgetown University
Abramson Cancer Center at Penn Medicine
Maisonneuve-Rosemont Hospital
University of Iowa
Intensity Therapeutics, Inc.
RAPT Therapeutics, Inc.
Mayo Clinic
M.D. Anderson Cancer Center
Hutchmed
Takeda
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University Hospital, Basel, Switzerland
SymBio Pharmaceuticals
University of Nebraska
Memorial Sloan Kettering Cancer Center
Columbia University
Abramson Cancer Center at Penn Medicine
Columbia University
TG Therapeutics, Inc.
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
Fujifilm Pharmaceuticals U.S.A., Inc.
Incyte Corporation
University of California, Davis
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Spectrum Pharmaceuticals, Inc
Gilead Sciences
Taiwan Liposome Company
City of Hope Medical Center
Shenzhen Institute for Innovation and Translational Medicine
Weill Medical College of Cornell University
Novartis
Hoffmann-La Roche
University Hospital, Essen
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Swiss Cancer Institute